The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | PET-CT and whole-body diffusion-weighted MRI to evaluate bone disease in newly diagnosed myeloma
Marco Talarico, MD, University of Bologna, Bologna, Italy, discusses a study involving newly diagnosed multiple myeloma (MM) patients undergoing positron emission tomography-computed tomography (PET-CT) and whole-body diffusion-weighted magnetic resonance imaging (MRI) to assess the diagnostic performance of both techniques using standardized criteria. The findings suggest that whole-body MRI has greater sensitivity than PET-CT in detecting focal and para skeletal lesions, though both methods show good concordance in detecting extramedullary disease. This study is ongoing; further data will be collected to confirm these findings. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
